Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

ABSTRACT:

SUBMITTER: Coleman RL 

PROVIDER: S-EPMC5715461 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature